• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice.阿斯科利尼布治疗慢性髓性白血病患者在现实临床实践中的安全性和有效性。
Blood Cancer J. 2021 Feb 9;11(2):16. doi: 10.1038/s41408-021-00420-8.
2
Asciminib as a new option in the treatment of chronic myeloid leukemia.阿塞西尼布作为慢性粒细胞白血病治疗的新选择。
Future Oncol. 2021 Dec;17(36):5003-5005. doi: 10.2217/fon-2021-1174. Epub 2021 Nov 18.
3
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.阿西替尼在 ABL 激酶抑制剂失败后的慢性髓性白血病中的应用。
N Engl J Med. 2019 Dec 12;381(24):2315-2326. doi: 10.1056/NEJMoa1902328.
4
Asciminib: the next-generation bullet for first-line treatment of chronic myeloid leukemia.阿西替尼：一线治疗慢性髓性白血病的新一代子弹。
Med. 2024 Aug 9;5(8):856-858. doi: 10.1016/j.medj.2024.07.001.
5
Overcoming TKI resistance in a patient with chronic myeloid leukemia using combination BCR-ABL inhibition with asciminib and bosutinib.使用阿斯科利尼布和博舒替尼联合抑制BCR-ABL克服慢性髓性白血病患者的TKI耐药性。
Am J Hematol. 2021 Aug 1;96(8):E293-E295. doi: 10.1002/ajh.26231. Epub 2021 May 25.
6
Asciminib in chronic myeloid leukemia: many questions still remain to be answered.阿伐替尼治疗慢性髓性白血病：仍有许多问题有待解答。
Blood Cancer J. 2021 Apr 29;11(4):81. doi: 10.1038/s41408-021-00475-7.
7
The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.ASCIMINIB 的特异性，一种治疗慢性髓性白血病的潜在药物，作为一种豆蔻酰口袋结合的 ABL 抑制剂，并分析其与 BCR-ABL1 激酶突变形式的相互作用。
Leuk Res. 2020 Nov;98:106458. doi: 10.1016/j.leukres.2020.106458. Epub 2020 Sep 29.
8
Clinical outcomes of chronic myeloid leukaemia patients taking asciminib through a Managed Access Programme (MAP) in Australia.澳大利亚接受管理准入计划（MAP）下服用 ASCIMIB 的慢性髓性白血病患者的临床结局。
Intern Med J. 2024 Jul;54(7):1214-1218. doi: 10.1111/imj.16446. Epub 2024 Jun 17.
9
Treatment-free remission after third-line therapy with asciminib in chronic myeloid leukemia with an atypical e19a2 BCR::ABL1 transcript and T315I mutation.在伴有非典型e19a2 BCR::ABL1转录本和T315I突变的慢性髓性白血病中，使用阿斯科利尼进行三线治疗后实现无治疗缓解。
Leukemia. 2024 Sep;38(9):2037-2040. doi: 10.1038/s41375-024-02327-2. Epub 2024 Jul 4.
10
Breaking the mold: asciminib as a standard-of-care of the therapeutic armamentarium of chronic myeloid leukemia in the upfront setting.打破常规：阿伐替尼作为一线慢性髓性白血病治疗武器库中的标准治疗药物。
Future Oncol. 2023 Mar;19(8):545-547. doi: 10.2217/fon-2023-0095. Epub 2023 Apr 11.

引用本文的文献

1
Real-World Efficacy Profile of Compassionate Use of Asciminib in an Italian, Multi-Resistant Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Patient Population.阿西替尼在意大利多耐药慢性期慢性髓性白血病（CML-CP）患者群体中同情用药的真实世界疗效概况。
Hematol Oncol. 2025 May;43(3):e70101. doi: 10.1002/hon.70101.
2
Molecular response with asciminib 20 mg QD in a patient intolerant to multiple TKIs.在一名对多种酪氨酸激酶抑制剂（TKIs）不耐受的患者中，使用阿西替尼20毫克每日一次的分子反应。
Ann Hematol. 2025 May;104(5):3007-3009. doi: 10.1007/s00277-025-06339-5. Epub 2025 Apr 7.
3
Asciminib in the treatment of chronic myeloid leukemia in chronic phase.阿伐替尼治疗慢性期慢性髓性白血病
Future Oncol. 2025 Mar;21(7):815-831. doi: 10.1080/14796694.2025.2464494. Epub 2025 Feb 12.
4
Asciminib in Advanced-Line Treatment of Chronic Myeloid Leukemia.阿伐替尼用于慢性髓性白血病的晚期治疗
Eur J Haematol. 2025 Feb;114(2):258-263. doi: 10.1111/ejh.14330. Epub 2024 Oct 21.
5
Therapeutic options for chronic myeloid leukemia following the failure of second-generation tyrosine kinase inhibitor therapy.第二代酪氨酸激酶抑制剂治疗失败后慢性髓性白血病的治疗选择
Front Oncol. 2024 Jul 29;14:1446517. doi: 10.3389/fonc.2024.1446517. eCollection 2024.
6
Genetic Landscape of Chronic Myeloid Leukemia and a Novel Targeted Drug for Overcoming Resistance.慢性髓性白血病的遗传特征图谱与克服耐药性的新型靶向药物
Int J Mol Sci. 2023 Sep 7;24(18):13806. doi: 10.3390/ijms241813806.
7
A Multicenter Retrospective Chart Review Study of Treatment and Disease Patterns and Clinical Outcomes of Patients with Chronic-Phase Chronic Myeloid Leukemia in Third-Line Treatment or with T315I Mutation.一项关于慢性期慢性髓性白血病患者三线治疗或T315I突变的治疗、疾病模式及临床结局的多中心回顾性病历审查研究。
Cancers (Basel). 2023 Aug 18;15(16):4161. doi: 10.3390/cancers15164161.
8
Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events.真实世界中使用波那替尼治疗慢性期慢性髓性白血病的经验：反应深度对生存的影响以及先前使用尼洛替尼对动脉闭塞事件的影响。
Blood Cancer J. 2023 Aug 11;13(1):122. doi: 10.1038/s41408-023-00891-x.
9
Refractory pancytopenia upon initiation of asciminib in tyrosine kinase inhibitor-resistant chronic myeloid leukemia.在酪氨酸激酶抑制剂耐药的慢性髓性白血病中，使用阿西替尼起始治疗时出现难治性全血细胞减少。
Int J Crit Illn Inj Sci. 2023 Apr-Jun;13(2):78-81. doi: 10.4103/ijciis.ijciis_85_22. Epub 2023 Jun 26.
10
Management of chronic myeloid leukemia in 2023 - common ground and common sense.2023 年慢性髓性白血病的管理——共识与常理。
Blood Cancer J. 2023 Apr 24;13(1):58. doi: 10.1038/s41408-023-00823-9.

本文引用的文献

1
The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.ASCIMINIB 的特异性，一种治疗慢性髓性白血病的潜在药物，作为一种豆蔻酰口袋结合的 ABL 抑制剂，并分析其与 BCR-ABL1 激酶突变形式的相互作用。
Leuk Res. 2020 Nov;98:106458. doi: 10.1016/j.leukres.2020.106458. Epub 2020 Sep 29.
2
Current Treatment Options for Chronic Myeloid Leukemia Patients Failing Second-Generation Tyrosine Kinase Inhibitors.第二代酪氨酸激酶抑制剂治疗失败的慢性髓性白血病患者的当前治疗选择
J Clin Med. 2020 Jul 15;9(7):2251. doi: 10.3390/jcm9072251.
3
Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study.波舒替尼治疗预处理慢性期慢性髓性白血病患者：4 期 BYOND 研究的主要结果。
Leukemia. 2020 Aug;34(8):2125-2137. doi: 10.1038/s41375-020-0915-9. Epub 2020 Jun 22.
4
Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors.专家意见——第二代酪氨酸激酶抑制剂耐药后的慢性髓性白血病的管理。
Leukemia. 2020 Jun;34(6):1495-1502. doi: 10.1038/s41375-020-0842-9. Epub 2020 May 4.
5
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.欧洲白血病网络 2020 年治疗慢性髓性白血病的建议。
Leukemia. 2020 Apr;34(4):966-984. doi: 10.1038/s41375-020-0776-2. Epub 2020 Mar 3.
6
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.阿西替尼在 ABL 激酶抑制剂失败后的慢性髓性白血病中的应用。
N Engl J Med. 2019 Dec 12;381(24):2315-2326. doi: 10.1056/NEJMoa1902328.
7
Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety.可用于慢性髓性白血病的酪氨酸激酶抑制剂：疗效与安全性
Front Oncol. 2019 Jul 3;9:603. doi: 10.3389/fonc.2019.00603. eCollection 2019.
8
The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression .新型变构抑制剂阿伐替尼易受ABCB1和ABCG2过表达介导的耐药影响。
Oncotarget. 2018 Feb 3;9(17):13423-13437. doi: 10.18632/oncotarget.24393. eCollection 2018 Mar 2.
9
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.达沙替尼治疗费城染色体阳性白血病的疗效和安全性：2 期 PACE 试验的最终 5 年结果。
Blood. 2018 Jul 26;132(4):393-404. doi: 10.1182/blood-2016-09-739086. Epub 2018 Mar 22.
10
The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.变构抑制剂 ABL001 能够实现对 BCR-ABL1 的双重靶向。
Nature. 2017 Mar 30;543(7647):733-737. doi: 10.1038/nature21702. Epub 2017 Mar 22.

Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice.

作者信息

Garcia-Gutiérrez Valentín, Luna Alejandro, Alonso-Dominguez Juan M, Estrada Natalia, Boque Concepcion, Xicoy Blanca, Giraldo Pilar, Angona Anna, Alvarez-Larrán Alberto, Sanchez-Guijo Fermin, Ramírez María José, Mora Elvira, Vélez Patricia, Rosell Ana, Colorado Araujo Mercedes, Cuevas Beatriz, Sagüés Miguel, Cortes Montserrat, Encinas Manuel Perez, Casado Montero Luis Felipe, Moreno Vega Melania, Serrano Luis, Gomez Valle, Garcia-Hernandez Carmen, Lakhwani Sunil, Paz Coll Antonio, de Paz Raquel, Suarez-Varela Sara, Fernandez-Ruiz Andrés, Perez Lopez Raul, Ortiz-Fernández Almudena, Jiménez-Velasco Antonio, Steegmann-Olmedillas Juan Luis, Hernández-Boluda Juan Carlos

机构信息

Hematology, Hospital Universitario Ramón y Cajal. IRYCIS, Madrid, Spain.

Hospital Universitario Fundación Jiménez Díaz, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), UAM, Madrid, Spain.

出版信息

Blood Cancer J. 2021 Feb 9;11(2):16. doi: 10.1038/s41408-021-00420-8.

DOI:10.1038/s41408-021-00420-8
PMID:33563899
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7873237/
Abstract
摘要